R3 Bio COO Tried to Bury 2-Hour Podcast, Denying Current 'Organ Sack' Work
Updated
Updated · Futurism · Jul 14
R3 Bio COO Tried to Bury 2-Hour Podcast, Denying Current 'Organ Sack' Work
1 articles · Updated · Futurism · Jul 14
Summary
A week before release, Skyline Drive said Alice Gilman asked to postpone her nearly 2-hour interview after discussing R3 Bio’s “organ sacks,” then said the company was not working on the concept “for now, period.”
Gilman did not dispute the interview’s accuracy, according to the podcast team, but recast her remarks as theory and opinion and vaguely described R3 Bio as a “federal asset,” suggesting undisclosed government ties.
The interview itself described ambitions to grow nonsentient, brainless humanoid bodies for organs and drug testing, while also outlining a nearer-term plan to reprogram monkey skin cells into organ systems and seek “monkey access” in Puerto Rico.
Those comments clash with R3 Bio’s public messaging: Wired reported in March that the startup was working on “organ sacks,” while its website now says it has “no ongoing work” on full-scale human organ fabrication.
The episode adds to scrutiny of a startup already criticized for opaque claims, with the host saying the bigger issue is not the bioethics alone but the gap between R3 Bio’s hype and what it has actually achieved.
Is R3 Bio's mission to replace animal testing just a cover for a more radical goal of full human body replacement?
Headless clones for organ harvesting: Is this a medical breakthrough or a bioethical nightmare fueled by Silicon Valley hype?
R3 Bio’s $100 Million Gamble: Organ Sacks, Federal Ties, and the Ethics Crisis Shaking Biotech in 2026
Overview
In February 2026, R3 Bio CEO Alice Gilman’s appearance on the Skyline Drive podcast brought the company’s controversial ambitions into the spotlight. Gilman discussed R3 Bio’s development of nonsentient 'organ sacks' for drug testing and hinted at deep government ties by calling R3 Bio a 'federal asset.' This statement sparked intense public and media scrutiny, raising questions about the company’s transparency and its relationship with federal agencies. Gilman’s later attempt to delay or edit the podcast fueled speculation that R3 Bio was trying to control the narrative, highlighting tensions between its public claims and private ambitions.